AIM Aim Immunotech stock Story

AIM -  USA Stock  

USD 2.11  0.06  2.77%

Aim Immunotech Market Capitalization is relatively stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 4.61 Million. Tangible Asset Value is expected to hike to about 23.8 M this year, although the value of Earnings before Tax will most likely fall to (10.3 M). If you are looking to grow your portfolio over time, you may want to summarize all of the essential forward indicators of your selected equities before buying their shares. In this article, we will summarize Aim Immunotech. We will analyze why Aim Immunotech investors may still consider a stake in the business. Aim Immunotech current probability of bankruptcy is over 66%. Are the company stakeholders still optimistic?
Published over six months ago
View all stories for Aim Immunotech | View All Stories
Check the odds of Aim Immunotech (NYSEMKT:AIM) to pull down in December
The firm shows a Beta (market volatility) of -0.2991, which signifies not very significant fluctuations relative to the market. Let's try to break down what Aim Immunotech's beta means in this case. As returns on the market increase, returns on owning Aim Immunotech are expected to decrease at a much lower rate. During the bear market, Aim Immunotech is likely to outperform the market. Even though it is essential to pay attention to Aim Immunotech historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Aim Immunotech exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Aim Immunotech has an expected return of -0.18%. Please be advised to confirm Aim Immunotech total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power to decide if Aim Immunotech stock performance from the past will be repeated at some point in the near future.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Aim Immunotech income statement, its balance sheet, and the statement of cash flows. Potential Aim Immunotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Aim Immunotech investors may use each financial statement separately, they are all related. The changes in Aim Immunotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aim Immunotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Aim Immunotech fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Aim Immunotech performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Aim Immunotech shares is the value that is considered the true value of the share. If the intrinsic value of AIM Aim Immunotech is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Aim Immunotech.
Please read more on our fundamental analysis page.

What is AIM Aim Immunotech Asset Breakdown?

Aim Immunotech reports assets on its Balance Sheet. It represents the amount of AIM Aim Immunotech resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect AIM Aim Immunotech volatility, please check the breakdown of all its fundamentals

How AIM Aim Immunotech utilizes its cash?

To perform a cash flow analysis of Aim Immunotech, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Aim Immunotech is receiving and how much cash it distributes out in a given period. The Aim Immunotech cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Aim Immunotech Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (11.19 Million)

Aim Immunotech Gross Profit

Aim Immunotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Aim Immunotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Aim Immunotech Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Breaking down the case for Aim Immunotech

The entity reported the last year's revenue of 196 K. Reported Net Loss for the year was (11.3 M) with loss before taxes, overhead, and interest of (753 K).
 2017 2018 2019 2020 (projected)
Book Value per Share13.355.153.543.64
Asset Turnover0.0280.0240.0080.008895

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aim Immunotech has an asset utilization ratio of 0.84 percent. This denotes that the company is making $0.008403 for each dollar of assets. An increasing asset utilization means that Aim Immunotech is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
14.8 M
Assets Non Current
10 M
Current Assets14.76 Million56.96
Assets Non Current10.01 Million38.65
Goodwill1.14 Million4.39

Over 3 percent hike for Aim Immunotech. What does it mean for stakeholders?

Skewness is down to 1.23. It may denote a possible volatility pull down. Aim Immunotech exhibits very low volatility with skewness of 1.23 and kurtosis of 4.66. However, we advise investors to further study Aim Immunotech technical indicators to make sure all market info is available and is reliable.

Our Final Takeaway

While some other companies in the biotechnology industry are either recovering or due for a correction, Aim Immunotech may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Aim Immunotech valuation and our trade advice on Aim Immunotech is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Aim Immunotech.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Aim Immunotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to